Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.
With a diverse pipeline targeting high-value indications such as Duchenne muscular dystrophy (DMD) and wet age-related macular degeneration (wet AMD (NASDAQ:AMD)), REGENXBIO has positioned itself as ...
REGENXBIO (RGNX) announced that AFFINITY DUCHENNE, the multi-center, open-label trial of RGX-202, a potential best-in-class genetherapy for Duchenne muscular dystrophy, has advanced to pivotal ...
Results that may be inaccessible to you are currently showing.